PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$16.56 -0.5  -3.0%

Last Trade - 24/09/21

Small Cap
Market Cap £344.0m
Enterprise Value £289.4m
Revenue £n/a
Position in Universe 3775th / 7172

BUZZ-Cantor starts PDS Biotech with 'overweight' on growth prospects

Mon 28th June, 2021 11:59am
** Brokerage Cantor Fitzgerald starts coverage on drug
developer  PDSB.O  with "overweight" rating; believes co has
promising pipeline of cancer and infectious diseases therapies
and that peak sales potential for co's lead immunotherapy
candidate, PDS0101, remains underappreciated
    ** Sets PT at $25, a premium of 127.3% to PDSB's last close
    ** Brokerage sees many upcoming potential stock-moving
catalysts including data from trials testing PDS0101 in advanced
human papillomavirus (HPV)- associated cancers and in advanced
cervical cancer
    ** Adds that two other potential cancer therapies - PDS0102 
and  PDS0103 - are also entering clinical testing in H1 of 2022
    ** Upwards earnings revision, driven by pipeline
advancements, should move the stock higher - Cantor
    ** Stock up 1.3% at $11.15 premarket
    ** Current avg. rating on stock is "buy"; median PT is
$17.50 - Refinitiv data

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.